Intravenous Immunoglobulin to Suppress Progression in a Patient With Advanced Breast Cancer

Intravenous immunoglobulin (IVIG) is used to treat various diseases and has anticancer effects that suppress metastases in animal models of sarcoma and melanoma. However, these effects have been observed in a limited number of clinical cases. We report the case of a patient with metastatic breast ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Kai-Liang, Chao, Ta-Chung, Chen, Ming-Han
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Breast Cancer Society 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250874/
https://www.ncbi.nlm.nih.gov/pubmed/35380017
http://dx.doi.org/10.4048/jbc.2022.25.e8
Descripción
Sumario:Intravenous immunoglobulin (IVIG) is used to treat various diseases and has anticancer effects that suppress metastases in animal models of sarcoma and melanoma. However, these effects have been observed in a limited number of clinical cases. We report the case of a patient with metastatic breast cancer in which long-term IVIG treatment stopped disease progression in the absence of salvage chemotherapy. The patient was treated with IVIG for the treatment of immune thrombocytopenia. Surprisingly, the lung and brain metastases were stabilized, and the patient achieved a progression-free interval of 29 months. More cases are needed to investigate and confirm the efficacy of IVIG in solid tumors in the future.

Ejemplares similares